Citations (67)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Shang-Chin Huang, Hung-Chih Yang & Jia-Horng Kao. (2020) Hepatitis B reactivation: diagnosis and management. Expert Review of Gastroenterology & Hepatology 14:7, pages 565-578.
Read now
Read now
Alessandra Tedeschi, Anna Maria Frustaci, Maddalena Mazzucchelli, Roberto Cairoli & Marco Montillo. (2017) Is HBV prophylaxis required during CLL treatment with ibrutinib?. Leukemia & Lymphoma 58:12, pages 2966-2968.
Read now
Read now
Cheng-Shyong Chang, Chien-Yu Tsai & Sheng-Lei Yan. (2017) Hepatitis B reactivation in patients receiving targeted therapies. Hematology 22:10, pages 592-598.
Read now
Read now
Ester Maria Orlandi, Chiara Elena & Elisa Bono. (2017) Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia. Leukemia & Lymphoma 58:7, pages 1764-1766.
Read now
Read now
Federica Sorà, Francesca Romana Ponziani, Luca Laurenti, Patrizia Chiusolo, Francesco Autore, Antonio Gasbarrini, Simona Sica & Maurizio Pompili. (2017) Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leukemia & Lymphoma 58:4, pages 993-995.
Read now
Read now
Mauro Viganò, Giuseppe Serra, Giovanni Casella, Glenda Grossi & Pietro Lampertico. (2016) Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders. Expert Opinion on Biological Therapy 16:7, pages 917-926.
Read now
Read now
Enaam Al Sobri, Zayed Zahrani, Eduardo Zevallos & Abdo Zuraiki. (2007) Imatinib-induced immune hepatitis: Case report and literature review. Hematology 12:1, pages 49-53.
Read now
Read now
Ricardo García-Muñoz, Alicia Galar, Cristina Moreno, Paula Rodríguez-Otero, Elena Panizo-Morgado, Mariano Ponz-Sarvisê, Mirian Fernandez-Alonso, Manuel Rubio, Juana Merino, Braulia Cuesta, Carlos Panizol & Felipe Prosper. (2007) Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825). Leukemia & Lymphoma 48:12, pages 2461-2464.
Read now
Read now
Articles from other publishers (59)
Ling‐Yi Wang, Sung‐Chao Chu, I‐Yun Chang & K. Arnold Chan. (2023)
Sex‐specific incidence of hepatitis B virus flares among
Bcr‐Abl
tyrosine kinase inhibitor users in Taiwan
. Pharmacoepidemiology and Drug Safety 32:12, pages 1368-1377.
Crossref
Crossref
Tian Yu, Weiming Li & Tao Yu. (2023) Management of chronic myelogenous leukemia with COVID-19 and hepatitis B. Frontiers in Oncology 13.
Crossref
Crossref
Gian Paolo Caviglia, Antonella Zorzi, Mario Rizzetto, Massimo Mirandola, Antonella Olivero & Giada Carolo. (2021) Hepatitis B Virus Reactivation upon Immunosuppression: Is There a Role for Hepatitis B Core-Related Antigen in Patients with Immune-Escape Mutants? A Case Report. Diagnostics 11:12, pages 2185.
Crossref
Crossref
Shailendra Prasad verma, Anil Kumar Tripathi, Nidhish Kumar & Suneel Kumar Gupta. (2021) Case reports of chronic myeloid leukemia and tuberculosis: Is imatinib the link between the two?. Indian Journal of Tuberculosis 68:3, pages 412-415.
Crossref
Crossref
Ling-Yi Wang, Sung-Chao Chu, Yin Lo, Yen-Yun Yang & K. Arnold Chan. (2021) Association of Bcr-Abl Tyrosine Kinase Inhibitors With Hepatitis B Virus Reactivation Requiring Antiviral Treatment in Taiwan. JAMA Network Open 4:4, pages e214132.
Crossref
Crossref
Delphine Rea. 2021. Chronic Myeloid Leukemia. Chronic Myeloid Leukemia
77
91
.
Graeme Smith, Jane Apperley, Dragana Milojkovic, Nicholas C. P. Cross, Letizia Foroni, Jenny Byrne, Andy Goringe, Anupama Rao, Jamshid Khorashad, Hugues Lavallade, Adam J. Mead, Wendy Osborne, Chris Plummer, Gail Jones & Mhairi Copland. (2020) A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. British Journal of Haematology 191:2, pages 171-193.
Crossref
Crossref
Sirina Ekpanyapong & K. Rajender Reddy. (2020) Hepatitis B Virus Reactivation. Clinics in Liver Disease 24:3, pages 317-333.
Crossref
Crossref
Joshua S. Davis, David Ferreira, Emma Paige, Craig Gedye & Michael Boyle. (2020) Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clinical Microbiology Reviews 33:3.
Crossref
Crossref
Eiichi Ogawa, Mike T. Wei & Mindie H. Nguyen. (2020) Hepatitis B Virus Reactivation Potentiated by Biologics. Infectious Disease Clinics of North America 34:2, pages 341-358.
Crossref
Crossref
Xiaoming Cheng, Takuro Uchida, Yuchen Xia, Regina Umarova, Chun-Jen Liu, Pei-Jer Chen, Anuj Gaggar, Vithika Suri, Marcus M. Mücke, Johannes Vermehren, Stefan Zeuzem, Yuji Teraoka, Mitsutaka Osawa, Hiroshi Aikata, Keiji Tsuji, Nami Mori, Shuhei Hige, Yoshiyasu Karino, Michio Imamura, Kazuaki Chayama & T. Jake Liang. (2020) Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. Journal of Clinical Investigation 130:6, pages 3205-3220.
Crossref
Crossref
Claudia Bettoni da Cunha-Riehm, Verena Hildebrand, Michaela Nathrath, Markus Metzler & Meinolf Suttorp. (2020) Vaccination With Live Attenuated Vaccines in Four Children With Chronic Myeloid Leukemia While on Imatinib Treatment. Frontiers in Immunology 11.
Crossref
Crossref
Giuseppe Indolfi, Mona Abdel-Hady, Sanjay Bansal, Dominique Debray, Françoise Smets, Piotr Czubkowski, Wendy van der Woerd, Marianne Samyn, Jörg Jahnel, Girish Gupte, Aglaia Zellos, Yael Mozer-Glassberg, Henkjan J. Verkade, Etienne Sokal & Björn Fischler. (2020) Management of Hepatitis B Virus Infection and Prevention of Hepatitis B Virus Reactivation in Children With Acquired Immunodeficiencies or Undergoing Immune Suppressive, Cytotoxic, or Biological Modifier Therapies. Journal of Pediatric Gastroenterology & Nutrition 70:4, pages 527-538.
Crossref
Crossref
Mar Riveiro-Barciela, Paula Gubern, Luisa Roade, Pau Abrisqueta, María José Carreras, Anna Farriols, Francesc Bosch, Rafael Esteban & María Buti. (2020) An electronic alert system increases screening for hepatitis B and C and improves management of patients with haematological disorders. Scientific Reports 10:1.
Crossref
Crossref
Shady Adnan Awad, Matti Kankainen, Teija Ojala, Perttu Koskenvesa, Samuli Eldfors, Bishwa Ghimire, Ashwini Kumar, Soili Kytölä, Mahmoud M. KamelCaroline A. Heckman, Kimmo Porkka & Satu Mustjoki. (2020) Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. Blood Advances 4:3, pages 546-559.
Crossref
Crossref
Asmaa Atteya, Aiman Ahmad, Dima Daghstani, Kamran Mushtaq & Mohamed A. Yassin. (2020) Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. Cancer Control 27:1, pages 107327482097659.
Crossref
Crossref
Danielle J. Smalls, Reagan E. Kiger, LeAnn B. Norris, Charles L. Bennett & Bryan L. Love. (2019) Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 39:12, pages 1190-1203.
Crossref
Crossref
Faisal Inayat, Fei Song, Nouman Safdar Ali, Muhammad Haseeb Aslam, Aishatu Aloma, Hilal Hachem & Muhammad Wasif Saif. (2018) Hepatitis B virus reactivation following imatinib therapy: A comparative review of 9 cases. Journal of Oncology Pharmacy Practice 25:6, pages 1500-1508.
Crossref
Crossref
Caterina Sagnelli, Mariantonietta Pisaturo, Federica Calò, Salvatore Martini, Evangelista Sagnelli & Nicola Coppola. (2019) Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention. World Journal of Gastroenterology 25:26, pages 3299-3312.
Crossref
Crossref
Yu-Hung Wang, Ja-Der Liang, Wang-Huei Sheng, Feng-Ming Tien, Chien-Yuan Chen & Hwei-Fang Tien. (2019) Hepatitis B reactivation during treatment of tyrosine kinase inhibitors—Experience in 142 adult patients with chronic myeloid leukemia. Leukemia Research 81, pages 95-97.
Crossref
Crossref
Sarah Atkins & Fiona He. (2019) Chemotherapy and Beyond. Infectious Disease Clinics of North America 33:2, pages 289-309.
Crossref
Crossref
Lidan Hou, Jie Zhao, Shaobing Gao, Tong JiTianyu Song, Yining LiJingjie WangChenlu GengMin LongJiang Chen, Hui LinXiujun CaiYong Cang. (2019) Restriction of hepatitis B virus replication by c-Abl–induced proteasomal degradation of the viral polymerase. Science Advances 5:2.
Crossref
Crossref
Welda E.H. Tjhoi, Kai Li, Chun-hui Shou, Wei-li Yang & Ji-ren Yu. (2019) Long-term adjuvant imatinib treatment for a patient who underwent complete resection of a localized recurrent gastrointestinal stromal tumor after preoperative imatinib treatment. Medicine 98:6, pages e14477.
Crossref
Crossref
Jian Li, Ming Wang, Bo Zhang, Xin Wu, Tian-Long Lin, Xiu-Feng Liu, Ye Zhou, Xin-Hua Zhang, Hao Xu, Li-Jing Shen, Jing Zou, Ping Lu, Dong Zhang, Wei-Jun Gu, Mei-Xia Zhang, Jian Pan & Hui Cao. (2018) Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors. World Journal of Gastroenterology 24:46, pages 5189-5202.
Crossref
Crossref
M. Reinwald, J.T. Silva, N.J. Mueller, J. Fortún, C. Garzoni, J.W. de Fijter, M. Fernández-Ruiz, P. Grossi & J.M. Aguado. (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clinical Microbiology and Infection 24, pages S53-S70.
Crossref
Crossref
Bettina M. Knoll & K. Seiter. (2018) Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature. Infection 46:3, pages 409-418.
Crossref
Crossref
L. Sarmati, M. Andreoni, G. Antonelli, W. Arcese, R. Bruno, N. Coppola, G.B. Gaeta, M. Galli, C. Girmenia, M. Mikulska, F. Pane, C.F. Perno, M. Picardi, M. Puoti, A. Rambaldi, V. Svicher, G. Taliani & G. Gentile. (2017) Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper. Clinical Microbiology and Infection 23:12, pages 935-940.
Crossref
Crossref
Rohit Loomba & T. Jake Liang. (2017) Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology 152:6, pages 1297-1309.
Crossref
Crossref
Livio Pagano, Alessandro Busca, Anna Candoni, Chiara Cattaneo, Simone Cesaro, Rosa Fanci, Gianpaolo Nadali, Leonardo Potenza, Domenico Russo, Mario Tumbarello, Annamaria Nosari, Franco Aversa, Federica Lessi, Marianna Criscuolo, Francesca Farina, Maria Chiara Tisi, Gloria Turri, Angelica Barone, Angelica Spolzino, Maria Ilaria Del Principe, Angela Maria Quinto, Roberta Di Blasi, Laura Maracci, Mitja Nabergoj, Benedetta Cambò, Anna Pegoraro, Francesco Marchesi, Silvia Pascale, Angela Passi, Melania Carlisi, Nicola Polverelli, Barbara Beggia, Benedetta Rambaldi, Lucia Prezioso & Marco Sanna. (2017) Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Reviews 31:2, pages 17-29.
Crossref
Crossref
C.S. Voican, O. Mir, P. Loulergue, M. Dhooge, C. Brezault, J. Dréanic, S. Chaussade, S. Pol & R. Coriat. (2016) Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Annals of Oncology 27:12, pages 2172-2183.
Crossref
Crossref
Ursula Wiedermann, Harald H. Sitte, Heinz Burgmann, Alexander Eser, Petra Falb, Heidemarie Holzmann, Maria Kitchen, Marcus Köller, Herwig Kollaritsch, Michael Kundi, Hans Lassmann, Ingomar Mutz, Winfried F. Pickl, Elisabeth Riedl, Maria Sibilia, Florian Thalhammer, Barbara Tucek, Werner Zenz & Karl Zwiauer. (2016) Impfungen bei Immundefekten/Immunsuppression – Expertenstatement und EmpfehlungenGuidelines for vaccination of immunocompromised individuals. Wiener klinische Wochenschrift 128:S4, pages 337-376.
Crossref
Crossref
Venessa Pattullo. (2016) Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clinical and Molecular Hepatology 22:2, pages 219-237.
Crossref
Crossref
Soheil Tavakolpour, Seyed Moayed Alavian & Shahnaz Sali. (2016) Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review. Hepatitis Monthly 16:4.
Crossref
Crossref
Man Fai Law, Rita Ho, Carmen K M Cheung, Lydia H P Tam, Karen Ma, Kent C Y So, Bonaventure Ip, Jacqueline So, Jennifer Lai, Joyce Ng & Tommy H C Tam. (2016) Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World Journal of Gastroenterology 22:28, pages 6484.
Crossref
Crossref
Delphine Rea. 2016. Chronic Myeloid Leukemia. Chronic Myeloid Leukemia
71
87
.
Toshihiko Ando, Kensuke Kojima, Hiroshi Isoda, Yuichiro Eguchi, Takashi Honda, Masatoshi Ishigami & Shinya Kimura. (2015) Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. International Journal of Hematology 102:3, pages 379-382.
Crossref
Crossref
Tuncer Temel, Eren Gunduz, Esmira Sadigova, Hava Uskudar Teke, Safak Meric Ozgenel & Aysegul Harmanci Ozakyol. (2015) Hepatitis B Virus Reactivation under
Treatment with Nilotinib. Euroasian Journal of Hepato-Gastroenterology 5:2, pages 112-114.
Crossref
Crossref
Venessa Pattullo. (2015) Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure. World Journal of Hepatology 7:7, pages 954.
Crossref
Crossref
Mark ReinwaldTobias BochWolf-Karsten HofmannDieter Buchheidt. (2016) Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. Biomarker Insights 10s3, pages BMI.S22430.
Crossref
Crossref
Robert P. Perrillo, Robert Gish & Yngve T. Falck-Ytter. (2015) American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy. Gastroenterology 148:1, pages 221-244.e3.
Crossref
Crossref
Ryo Inose, Kouichi Hosomi, Binawool Park, Mai Fujimoto & Mitsutaka Takada. (2014) Signal Detection of hepatitis B and hepatitis C by molecularly-targeted drugs for cancer:. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 40:5, pages 268-277.
Crossref
Crossref
Hisashi Takei, Takeki Mitsui, Naru Sato, Akio Saito, Takumi Hoshino, Hiromi Koiso, Makiko Takizawa, Akihiko Yokohama, Takayuki Saito, Norifumi Tsukamoto, Kazuhiro Murakami, Hiroshi Handa & Yoshihisa Nojima. (2014) A Newly Diagnosed CML-CP HBV Carrier was Safely Treated with Dasatinib and Entecavir. The Kitakanto Medical Journal 64:1, pages 51-55.
Crossref
Crossref
Jessica P Hwang, Michael J Fisch, Anna S-F Lok, Hong Zhang, John M Vierling & Maria E Suarez-Almazor. (2013) Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer 13:1.
Crossref
Crossref
Jessica P. Hwang, John M. Vierling, Andrew D. Zelenetz, Susan C. Lackey & Rohit Loomba. (2012) Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Supportive Care in Cancer 20:11, pages 2999-3008.
Crossref
Crossref
Cristina Martínez Pascual, Mariano Valdés Mas, Jesús Miguel de la Peña Moral & Manuel Miras López. (2011) Hepatitis fulminante por imatinib en un paciente con leucemia mieloide crónica. Medicina Clínica 137:7, pages 329-330.
Crossref
Crossref
Marcio Nucci, Nair Bijay & Elias Anaissie. 2010. Leukemias: Principles and Practice of Therapy. Leukemias: Principles and Practice of Therapy
392
410
.
Navin Anthony, James Shanks & Howard Terebelo. (2010) Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate. Leukemia Research 34:9, pages 1250-1251.
Crossref
Crossref
Onder Tonyali, Ugur Coskun, Ramazan Yildiz, Tarkan Karakan, Umut Demirci, Nalan Akyurek, Mustafa Benekli & Suleyman Buyukberber. (2009) Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. Medical Oncology 27:3, pages 768-773.
Crossref
Crossref
Evgeny Klyuchnikov, Nicolaus Kröger, Tim H. Brummendorf, Bettina Wiedemann, Axel Rolf Zander & Ulrike Bacher. (2010) Current Status and Perspectives of Tyrosine Kinase Inhibitor Treatment in the Posttransplant Period in Patients with Chronic Myelogenous Leukemia (CML). Biology of Blood and Marrow Transplantation 16:3, pages 301-310.
Crossref
Crossref
Baidehi Maiti, Sebouh Setrakian & Hamed A Daw. (2009) Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report. Cases Journal 2:1.
Crossref
Crossref
Byung Woog Kang, Soo Jung Lee, Joon Ho Moon, Shi-Nae Kim, Yee Soo Chae, Jong Gwang Kim, Yoon-Jin Hwang & Sang-Kyun Sohn. (2009) Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. International Journal of Hematology 90:3, pages 383-387.
Crossref
Crossref
Cara K. Fraser, Stephen J. Blake, Kerrilyn R. Diener, A. Bruce Lyons, Michael P. Brown, Timothy P. Hughes & John D. Hayball. (2009) Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Experimental Hematology 37:2, pages 256-265.
Crossref
Crossref
Thomas Yau, Pierre Chan, Kelvin K. Ng, Sin Ho Chok, Tan To Cheung, Sheung Tat Fan & Ronnie T. Poon. (2009) Phase 2 open‐label study of single‐agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B–endemic Asian population. Cancer 115:2, pages 428-436.
Crossref
Crossref
Shilen Lakhani, Lev Davidson, Dennis A. Priebat & Averell H. Sherker. (2008) Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy. Hepatology International 2:4, pages 498-499.
Crossref
Crossref
William M Lee & Emmanuel Seremba. (2008) Etiologies of acute liver failure. Current Opinion in Critical Care 14:2, pages 198-201.
Crossref
Crossref
Thomas Lehrnbecher, Ulrike Koehl, Boris Wittekindt, Konrad Bochennek, Lars Tramsen, Thomas Klingebiel & Stephen J Chanock. (2008) Changes in host defence induced by malignancies and antineoplastic treatment: implication for immunotherapeutic strategies. The Lancet Oncology 9:3, pages 269-278.
Crossref
Crossref
Haitao Guo, Tianlun Zhou, Dong Jiang, Andrea Cuconati, Guang-Hui Xiao, Timothy M. Block & Ju-Tao Guo. (2007) Regulation of Hepatitis B Virus Replication by the Phosphatidylinositol 3-Kinase-Akt Signal Transduction Pathway. Journal of Virology 81:18, pages 10072-10080.
Crossref
Crossref
Edmundo A. Rodriguez-Frias & William M. Lee. (2007) Cancer Chemotherapy II: Atypical Hepatic Injuries. Clinics in Liver Disease 11:3, pages 663-676.
Crossref
Crossref
Parisa Sinai, Rance E. Berg, J. Marshall Haynie, Merrill J. Egorin, Robert L. IlariaJrJr & James Forman. (2007) Imatinib Mesylate Inhibits Antigen-Specific Memory CD8 T Cell Responses In Vivo. The Journal of Immunology 178:4, pages 2028-2037.
Crossref
Crossref